Mobile Observation Of Depression (MOOD) platform for digital phenotyping

位于苏塞克斯创新中心的Emteq有限公司正在开发一种可穿戴数字平台，可以实时客观地监测抑郁症的新标志物。世界卫生组织（WHO）估计，全球有超过3亿人患有抑郁症。在英国，高达10%的人在人生的某个阶段会遭受抑郁症的折磨；每年有超过5700万张抗抑郁药处方（英国，2014年）。世界范围内抑郁症发病率的上升是由于压力的增加和生活方式的改变。治疗一位抑郁症患者的经济成本为每人每年2085英镑，生产力损失每年高达75亿英镑。大多数精准医学方法寻找遗传或分子疾病标记。然而，虽然囊性纤维化等一些疾病有很强的遗传影响，但双胞胎研究表明，在可预防死亡的十大原因中，基因只起了很小的预测作用。所有十大过早死亡原因都有很强的行为影响，因此基于数字表型的预测分析具有拯救生命的巨大潜力。目前，临床医生还没有技术可以客观地测量重度抑郁症患者的情绪反应。在临床实践中，对症状和体征的评估和记录依赖于患者的主观回忆和他们当天感觉的“快照”。在这方面，一个在日常活动中进行客观监测的系统可能会对治疗分层和依从性产生巨大影响，并了解幸福的个人驱动因素。我们正在与心理健康领域的领先专家（MindTech, Sussex Partnership NHS Trust）合作，开发用于患者诊断、分层和治疗监测的“MOOD”平台。苏塞克斯合作伙伴NHS信托基金在包括社区服务在内的260多个站点运营，为155万人提供服务。MindTech在确保充分的公众患者代表、用户界面设计和临床路径建议方面发挥了重要作用。我们在建立商业和学术合作伙伴的国际网络方面投入了大量资金。成功的项目交付将巩固我们作为行业领先创新者的声誉，也是我们颠覆抑郁症治疗和筛查市场雄心勃勃的商业战略的第一步。”

"Emteq Ltd, based at the Sussex Innovation Centre, is developing a wearable digital platform that allows real-time objective monitoring of novel markers of depression.The World Health Organization (WHO) estimates more than 300m people are living with depression. In the UK, up to 10% of people will suffer from depression at some point in their lives; accounting for over 57m annual antidepressant prescriptions (England, 2014). The rising incidence of depression worldwide is attributed to increased stress and changing lifestyle. The economic cost of treating a patient with depression is £2,085/person/year and productivity losses account for £7.5b annually.Most precision medicine approaches look for genetic or molecular disease markers. However, whilst some conditions such as cystic fibrosis have and strong genetic influence, twin studies show that for the top ten causes of preventable deaths, genes contribute only a minor predictive role. All of the top ten causes of premature death have a strong behavioural influence, therefore predictive analytics based on digital phenotyping has huge potential to save lives.Currently, no technology is available for clinicians to measure emotional responses objectively in people with major depression. In clinical practice, assessment and documentation of symptoms and signs relies on the patients' subjective recall and a 'snapshot' of how they are feeling on the day. In this respect, a system for objective monitoring during day-to-day activities could have a tremendous impact on treatment stratification and compliance, and understanding individual drivers of happiness.We are collaborating with leading specialists in mental health (MindTech, Sussex Partnership NHS Trust), to develop the 'MOOD' platform for use in patient diagnosis, stratification and treatment monitoring.Sussex Partnership NHS Trust operates from over 260 sites, including community services, and serves a population of 1.55 million people. MindTech is instrumental in ensuring adequate Public Patient Representation, user interface design and advice on clinical pathways.We have invested heavily in building an international network of commercial and academic partners. Successful project delivery will cement our reputation as leading innovators within the industry and is the first step in an ambitious commercial strategy to disrupt the depression treatment and screening markets."